Press Releases

Press Releases

November 12, 2019
AVISE® Testing Revenue Drives 27% Revenue Growth SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis
October 29, 2019
SAN DIEGO , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today
October 24, 2019
SAN DIEGO , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (Nasdaq: HZNP) to measure methotrexate polyglutamates (MTXPGs), the active metabolites of methotrexate (MTX) in the MIRROR Randomized Controlled Trial
October 15, 2019
First ever prospective randomized multicenter clinical utility study shows the favorable impact of AVISE® Lupus on clinical decision-making and patient management SAN DIEGO , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum
September 18, 2019
San Diego, CA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,
Displaying 1 - 10 of 18